Disclosure Information
|
|
- Victoria Harrell
- 5 years ago
- Views:
Transcription
1 Disclosure Information Rebecca Fitzgerald holds patents for Cytosponge and related assays which have been licensed by the Medical Research Council to Covidien (now Medtronic)
2 Precision early diagnosis of oesophageal cancer using pill on a string Rebecca Fitzgerald MD. FMedSci Hon. Consultant Gastroenterologist, Cambridge University NHS Hospitals Trust Professor of Cancer Prevention and MRC Programme Leader MRC Cancer Unit, Hutchison-MRC Research Centre University of Cambridge
3 Life history of cancer Cell S Nik-Zainal et al 149;
4 Main Types of Oesophageal Cancer Squamous cell carcinoma Men= women Tobacco smoke Alcohol Thermal injury Micronutrient deficiency Adenocarcinoma Men> women Reflux Obesity Dysphagia, weight loss, GI bleeding. F. Lordick. Oesophageal Cancer: ESMO Clinical Practice Guidelines. Ann Oncol (2016) 27 (suppl 5): v50-v57
5 Global annual incidence of oesophageal cancer Males Adenocarcincoma Squamous cell carcinoma Females Smyth, E. C.Fitzgerald RC et al. (2017) Oesophageal cancer Nat. Rev. Dis. Primers doi: /nrdp
6 Trends for oesophageal adenocarcinoma Male Female UK Data on 114,494 EACs diagnosed in England between 1971 and 2013 courtesy Judith Offman
7 Survival from oesophageal cancer 480,000 new diagnoses per annum globally 450,000 cancer deaths per annum globally Overall survival 13% (worse in developing countries) Improving to 40% if detected early enough for curative therapy chemo, radiotherapy, surgery
8 Oesophageal cancer subtypes and precursor lesions Barrett s to adenocarcinoma Squamous dysplasia to Squamous cell carcinoma
9 Pathogenesis of oesophageal cancer Smyth, E. C. et al. (2017) Oesophageal cancer Nat. Rev. Dis. Primers doi: /nrdp
10 Barrett s progression rates and survival Non-dysplastic Barrett s LGD HGD Intramucosal cancer Advanced Cancer Progression rate %/year 5-year survival >90% 65% <15% (Desai Gut 2011, Hvid-Jensen NEJM, 2011, Duits, Gut 2014, Bhat, JNCI 2011)
11 NICE approved treatments for early cancer and dysplasia in 2015 NICE ruling for LGD 2 randomised controlled trials: Dysplasia trial Shaheen et al NEJM 2009; LGD SURF trial JAMA 2014
12 Reasons for LATE diagnosis of oesophageal adenocarcinoma - Patients and doctors wait until alarm" symptoms - Most patients at risk are not investigated - Endoscopy is invasive and expensive - White light endoscopy has limited resolution to detect focal dysplasia Oesophageal cancer is a public health concern and we need to develop an alternative safe, minimally invasive, affordable test Chief Medical Officer report 2008
13 Paradigm shift for early diagnosis in the esophagus: Cytosponge Technology Objective biomarker assays for diagnosis and risk stratification Non-endoscopic cell collection Collect along entire oesophagus and minimise sampling bias
14 William Croone 1680 "for the support of a lecture and illustrative experiment for the advancement of natural knowledge
15 Device considerations Low cost Ease of administration Stability of device (transportation and storage) Acceptability Kadri S.Fitzgerald RC BMJ 2010; 341: c4372 (BEST1) Ross-Innes Fitzgerald PLOS Medicine 2015; doi: (BEST2)
16 Biomarker critical for a clinical Cytosponge test Gene expression level(dct) NE BE GC NE BE GC NE BE GC DDC HOXB5 Stomach Barrett s Sq. Oes TFF3 Antibody to TFF3 Lao-Sirieix et al. GUT, 2009
17 Biomarker considerations Storage and transport of sample Assay design and applicability (Immunohistochemistry vs sequencing) Assay to GCLP Scoring and assessment Cost of assay
18 Studies BEST1 (500 patients) Study design Primary care Patients with reflux Endoscopy as gold standard BEST2 (1,110 patients) Study design Hospital setting Barrett s cases and controls (reflux) Endoscopy as gold standard Main Outcomes - Feasibility in primary care - Safety - Acceptability Main Outcomes - Safety - Acceptability - Accuracy Kadri S.Fitzgerald RC BMJ 2010; 341: c4372 (BEST1) Ross-Innes Fitzgerald PLOS Medicine 2015; doi: (BEST2)
19 Studies BEST1 (500 patients) Study design Primary care Patients with reflux Endoscopy as gold standard BEST2 (1,110 patients) Study design Hospital setting Barrett s cases and controls (reflux) Endoscopy as gold standard Main Outcomes - Feasibility in primary care - Safety - Acceptability Main Outcomes - Safety - Acceptability - Accuracy Kadri S.Fitzgerald RC BMJ 2010; 341: c4372 (BEST1) Ross-Innes Fitzgerald PLOS Medicine 2015; doi: (BEST2)
20 Summary of data > 2,000 patients Safe Acceptable 80% preferred Cytosponge to endoscopy Often tolerated better than endoscopy (p=0.0003) median 6 (IQR 5-8)
21 Cytosponge-TFF3 performance Sensitivity 79.9% Sensitivity increases with length (84% 2 cm and 87% 3 cm) Sensitivity 94% if remove inadequate samples (as per cervical screening) Specificity 92-94% Kadri S.Fitzgerald RC BMJ 2010; 341: c4372 (BEST1) Ross-Innes Fitzgerald PLOS Medicine 2015; doi: (BEST2)
22 Health Economics analyses Benaglia T Gastroenterology Jan; 144: microsimulation models using BEST2 trial data Screening patients with GERD by Cytosponge with follow-up endoscopy confirmation compared with endoscopy has favourable QALYs and ICERs CISNET Consortium Heberle CR.Hur C et al Clin Gastroenterol Hepatol 2017
23 Barrett s ESophagus Trial 3 Randomised Trial in Primary Care n = 10,000 Normal care for reflux or Offer of Cytosponge + usual care Primary objective Number of cases Barrett s diagnosed across two arms Secondary objectives Cost-effectiveness of the Cytosponge TM test vs standard of care Acceptability to patients and primary care clinicians 23
24 Where could Cytosponge fit into the clinical pathway? - Possible cancer symptoms endoscopy - Higher risk groups (Barrett s, male sex, white race, persistent heartburn, abdominal obesity, smokers, family history) - Investigation for all reflux/dyspepsia consulters Cytosponge - Population screening (as performed for colon, cervix)? Cytosponge Encourage early consultation First cancer symptom First GP visit GP diagnostic tests Hospital referral endoscopy Diagnosis & treatment plan Start treatment Primary care Secondary care
25 What next if TFF3 positive? Heartburn Symptoms Screening with Cytosponge TM test TFF3 negative test Patients discharged from screening programme TFF3 positive test Endoscopy
26 Using mutations to track Cancer Evolution Jos Jonkers Cancer Discovery 2012;2:
27 Is Cytosponge sampling sufficient to identify the invading clone(s)? Cancer SJ Leedham.NA Wright Gut 2008; 57:
28 Cytosponge captures entire clonal architecture 1 Clone 1 Clone 2 Clone 3 Clone 4 Clone 5 Clone 6 Clone 1 Clone 2 Clone 3 Clone 4 Clone 5 Clone 6 X axis for each clone chr 1-23 Y axis Variant Allele Fraction for each mutation Ross-Innes et al Nature Genetics 47; 2015
29 Molecular genetic heterogeneity Secrier M.Fitzgerald RC Nature Genetics 2016
30 Recurrent TP53 driver mutations 6/8=75% TP % cases have TP53 mutation Dulak et al Nature Genetic 2014 (TCGA) Weaver et al Nature Genetics 2014 (ICGC) Murugaesu N et al. Cancer Discovery 2015
31 Driver gene mutations in 551 oesophageal adenocarcinomas ICGC data Frankell A Fitzgerald RC unpublished
32 Mutation prevalence in Barrett s Never-dysplastic BE (f/up to 10 yrs) BE with high grade dysplasia Oesophageal adenocarcinoma Weaver et al Nature Genetics 2014
33 Dramatic increase copy number Alterations in invasive disease EAC: Sum of copy number gain/loss Barrett s: Sum of copy number gain/loss N=30 normal/barrett/s/adenocarcinoma trios Ross-Innes et al Nature Genetics 47; 2015
34 Reconstructing the life-history of Oesophageal Adenocarcinoma Life Oesophageal ICGC data in The evolutionary history of 2,658 Cancers biorxiv under review Nature Genetics 2017
35 Ordering of mutations and implications for biomarkers Screening window for curative intervention Never-dysplastic BE BE with high grade dysplasia Early invasive EAC Metastatic EAC Boundary Boundary Boundary Recurrently mutated genes TP53 SMAD4 (12%) Copy number (>80%) (70-80%) Multiple other mutated genes e.g. ARID1A, SMARCA4?Diversity measures
36 Risk stratification panel Given the sample is called HIGH RISK: the probability of being a true negative: 13% (5-27%) the probability of being a true positive: 87% (73-95%) 9 negative + 59 HGD were classified as high risk" Given the sample is called LOW RISK: the probability of being a true negative: 162/162 ( %) the probability of being a true positive: 0/162 (0.01-4%) In our data set: 162 negatives + 0 HGD were classified as low risk (Age, BMI, Barrett s length, atypia, copy number, p53 status) (BEST2 n=468)
37 Ongoing research with diagnostic test Improve risk stratification Automated slide reading for TFF3 One platform for diagnosis and stratification e.g. DNA methylation + mutation Near bedside test Incorporate other diagnostic information
38 Methylation panel on Cytopsonge 143 Controls NDBO TFF3 BEST1 TFF3 BEST2 Methylation AUC 83.6% 86.2% 90.4% Chettouh H.Fitzgerald RC et al Gut 2017
39 Precision diagnosis Heartburn Symptoms Screening with Cytosponge TM test TFF3 negative test Patients discharged from screening programme TFF3 positive test Risk stratification using panel of biomarkers Low risk High risk Repeat Cytosponge TM every 3-5 yrs Endoscopy + biopsy Standard management based on clinical result
40 Global perspective Reasons for late diagnosis: - Lack of education - Affordability - Access Cancer patients need better care, not just more technology Richard Sullivan, CS Pramesh, CM Booth Nature; Comment Sept 2017
41 High incidence areas of squamous cell carcinoma in China and Iran Feicheng Yanting
42 Screening: 40 years since Wilson and Junger and now in a genomic age Evidence based - Should respond to an unmet need - Objectives of screening clearly defined at the outset - Scientific evidence to define the target population - Scientific evidence for programme effectiveness Implementation - Quality assurance - Implementation strategy Patient centred - Patient considerations for equity and informed choice - Evidence that benefits outweigh harms Adapted from Anderman Dery et al Bulletin of WHO 2017
43 The future of cancer prevention? Self testing Bill Gates and Jess Bezos pour millions into new cancer test
44 Multi-analyte cancer blood test When weighted for actual incidence in the U.S., we estimate the sensitivity of CancerSEEK to be 55%. Joshua D. Cohen et al. Science 2018;science.aar3247
45 Early Detection Economics The jury is still out on the question of whether Precision Cancer Medicine will save or cost money to the NHS (the literature suggests more) Cancer Research UK 2014 Report suggesting that if cancers presently diagnosed at Stage 3 and 4 were halved by 2024, the saving to the NHS would be 257M/year. 6
46 Acknowledgments
Barrett s Esophagus: Old Dog, New Tricks
Barrett s Esophagus: Old Dog, New Tricks Stuart Jon Spechler, M.D. Chief, Division of Gastroenterology, VA North Texas Healthcare System; Co-Director, Esophageal Diseases Center, Professor of Medicine,
More informationBarrett s Esophagus. Abdul Sami Khan, M.D. Gastroenterologist Aurora Healthcare Burlington, Elkhorn, Lake Geneva, WI
Barrett s Esophagus Abdul Sami Khan, M.D. Gastroenterologist Aurora Healthcare Burlington, Elkhorn, Lake Geneva, WI A 58 year-old, obese white man has had heartburn for more than 20 years. He read a magazine
More informationScreening of Barrett: Is it cost-effective? Is there a high-risk population? T Ponchon Ed. Herriot Hospital Lyon, France
Screening of Barrett: Is it cost-effective? Is there a high-risk population? T Ponchon Ed. Herriot Hospital Lyon, France Barrett s esophagus (BE) is an acquired condition in which the normal squamous epithelium
More informationPresent Day Management of Barrett s Esophagus
Slide 1 Present Day Management of Barrett s Esophagus Kinnari R. Kher, M.D. Slide 2 Goals Risk factors for development of Barrett s esophagus Risks for progression to Esophageal Adenocarcinoma Current
More informationEverything Esophagus: Barrett s Esophagus. Nicholas Shaheen, MD, MPH Center for Esophageal Diseases and Swallowing University of North Carolina
Everything Esophagus: Barrett s Esophagus Nicholas Shaheen, MD, MPH Center for Esophageal Diseases and Swallowing University of North Carolina The Most Important Thing Stayed the Same Adenocarcinoma A
More informationAccepted Manuscript. CGH Editorial: Sound the Alarm for Barrett s Screening! Tarek Sawas, M.D., M.P.H., David A. Katzka, M.D
Accepted Manuscript CGH Editorial: Sound the Alarm for Barrett s Screening! Tarek Sawas, M.D., M.P.H., David A. Katzka, M.D PII: S1542-3565(18)31093-0 DOI: 10.1016/j.cgh.2018.10.010 Reference: YJCGH 56132
More informationHistory. Prevalence at Endoscopy. Prevalence and Reflux Sx. Prevalence at Endoscopy. Barrett s Esophagus: Controversy and Management
Barrett s Esophagus: Controversy and Management History Norman Barrett (1950) Chronic Peptic Ulcer of the Oesophagus and Oesophagitis Allison and Johnstone (1953) The Oesophagus Lined with Gastric Mucous
More informationBarrett's Esophagus: Sorting Out the Controversy
Barrett's Esophagus: Sorting Out the Controversy Learning Objectives 1. Identify the challenges in screening for Barrett s esophagus 2. Demonstrate comprehension of the risk of progression of Barrett s
More informationTargeting care in Barrett s oesophagus
HEPATO-GASTROENTEROLOGY Clinical Medicine 2014 Vol 14, No 6: s78 s83 Targeting care in Barrett s oesophagus Authors: Sebastian Zeki A and Rebecca C Fitzgerald B ABSTRACT Barretts oesophagus represents
More informationBarrett s Esophagus: State of the Art. Food Getting Stuck
Barrett s Esophagus: State of the Art Nicholas J. Shaheen, MD, MPH Center for Esophageal Diseases and Swallowing University of North Carolina SOM Food Getting Stuck 73-year-old retired Wilmington police
More informationChanges to the diagnosis and management of Barrett s Oesophagus
Changes to the diagnosis and management of Barrett s Oesophagus A review of the new BSG and NICE guidelines and best practice Anjan Dhar DM, MD, FRCPE, AGAF, MBBS (Hons.), Cert. Med. Ed Senior Lecturer
More informationMANAGEMENT OF BARRETT S RELATED NEOPLASIA IN 2018
MANAGEMENT OF BARRETT S RELATED NEOPLASIA IN 2018 Sachin Wani Medical Director Esophageal and Gastric Center Division of Gastroenterology and Hepatology University of Colorado Anschutz Medical Campus DISCLOSURES
More informationWhat s New in the Management of Esophageal Disease
What s New in the Management of Esophageal Disease Philip O. Katz, MD Chairman, Division of Gastroenterology Einstein Medical Center Philadelphia Clinical Professor of Medicine Jefferson Medical College
More informationThe National Oesophago-gastric Cancer Awareness Campaigna locality outcome analysis from County Durham
The National Oesophago-gastric Cancer Awareness Campaigna locality outcome analysis from County Durham Anjan Dhar DM, MD, FRCPE, AGAF, MBBS (Hons.), Cert. Med. Ed Reader in Medicine, Durham University
More informationManagement of Barrett s: From Imaging to Resection
Management of Barrett s: From Imaging to Resection Michael Wallace, MD, MPH, FACG Professor of Medicine Mayo Clinic Florida Goals of Endoscopic Evaluation in Barrett s Detect Barrett s and dysplasia Reduce/eliminate
More informationLearning Objectives:
Crescent City GI Update 2018 Ochsner Clinic, NOLA Optimizing Endoscopic Evaluation of Barrett s Esophagus What Should I Do in My Practice? Gregory G. Ginsberg, M.D. Professor of Medicine University of
More informationGenomic Diversity in Barrett s esophagus predicts long term progression.., Soesterberg, Prof. dr. Sheila Krishnadath
Genomic Diversity in Barrett s esophagus predicts long term progression.., Soesterberg, Prof. dr. Sheila Krishnadath 14-03-2018 Esophageal squamous cell carcinoma Risk factors - Alcohol - Smoking - Male
More informationEsophageal adenocarcinoma is a cancer with increasing
GASTROENTEROLOGY 2013;144:62 73 CLINICAL ALIMENTARY TRACT Health Benefits and Cost Effectiveness of Endoscopic and Nonendoscopic Cytosponge Screening for Barrett s Esophagus TATIANA BENAGLIA, 1 LINDA D.
More informationBarrett s Esophagus: Ablate Everyone?
Nicholas J. Shaheen, MD, MPH, FACG Barrett s Esophagus: Ablate Everyone? Nicholas J. Shaheen, MD, MPH, FACG Center for Esophageal Diseases and Swallowing University of North Carolina Greetings from UNC,
More informationAGA SECTION. Gastroenterology 2016;150:
Gastroenterology 2016;150:1026 1030 April 2016 AGA Section 1027 Procedural intervention (3) Upper endoscopy indications 3 6 Non-response of symptoms to a 4 8 week empiric trial of twice-daily PPI Troublesome
More informationScreening Patients for Barrett s Esophagus with Cytosponge Coupled with Trefoil Factor 3 Expression Compared to Endoscopy
Pacific University CommonKnowledge School of Physician Assistant Studies Theses, Dissertations and Capstone Projects Summer 8-13-2016 Screening Patients for Barrett s Esophagus with Cytosponge Coupled
More informationGastrointestinal pathology 2018 lecture 2. Dr Heyam Awad FRCPath
Gastrointestinal pathology 2018 lecture 2 Dr Heyam Awad FRCPath Eosinophilic esophagitis Incidence of eosinophilic gastritis is increasing. Symptoms: food impaction and dysphagia. Histology: infiltration
More informationAblation for Barrett s Esophagus: Burn or Freeze
Ablation for Barrett s Esophagus: Burn or Freeze John R. Saltzman MD Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School Disclosures No relevant disclosures
More informationSCREENING FOR BOWEL CANCER USING FLEXIBLE SIGMOIDOSCOPY REVIEW APPRAISAL CRITERIA FOR THE UK NATIONAL SCREENING COMMITTEE
SCREENING FOR BOWEL CANCER USING FLEXIBLE SIGMOIDOSCOPY REVIEW APPRAISAL CRITERIA FOR THE UK NATIONAL SCREENING COMMITTEE The Condition 1. The condition should be an important health problem Colorectal
More informationGregory G. Ginsberg, M.D.
Radiofrequency Ablation for Barrett s Esophagus with HGD Gregory G. Ginsberg, M.D. Professor of Medicine University of Pennsylvania School of Medicine Abramson Cancer Center Gastroenterology Division Executive
More informationHiatal Hernias and Barrett s esophagus. Dr Sajida Ahad Mercy General Surgery
Hiatal Hernias and Barrett s esophagus Dr Sajida Ahad Mercy General Surgery Objectives Identify the use of different diagnostic modalities for hiatal hernias List the different types of hiatal hernias
More informationEpidemiology, aetiology and the patient pathway in oesophageal and pancreatic cancers
Epidemiology, aetiology and the patient pathway in oesophageal and pancreatic cancers Dr Ian Chau Consultant Medical Oncologist Women's cancers Breast cancer introduction 3 What profession are you in?
More informationEndoscopic Management of Barrett s Esophagus
Endoscopic Management of Barrett s Esophagus Sammy Ho, MD Director of Pancreaticobiliary Services and Endoscopic Ultrasound Montefiore Medical Center Barrett s Esophagus Consequence of chronic GERD Mean
More informationOriginal article INTRODUCTION
Diseases of the Esophagus (2014), DOI: 10.1111/dote.12166 Original article A Barrett s esophagus registry of over 1000 patients from a specialist center highlights greater risk of progression than population-based
More informationCurrent Management: Role of Radiofrequency Ablation
Esophageal Adenocarcinoma And Barrett s Esophagus: Current Management: Role of Radiofrequency Ablation Ketan Kulkarni, MD Regional Gastroenterology Associates of Lancaster INTRODUCTION The prognosis of
More informationACG Clinical Guideline: Diagnosis and Management of Barrett s Esophagus
ACG Clinical Guideline: Diagnosis and Management of Barrett s Esophagus Nicholas J. Shaheen, MD, MPH, FACG 1, Gary W. Falk, MD, MS, FACG 2, Prasad G. Iyer, MD, MSc, FACG 3 and Lauren Gerson, MD, MSc, FACG
More informationComparison of Endoscopic and Clinical Characteristics of Patients with Familial and Sporadic Barrett s Esophagus
DOI 10.1007/s10620-011-1620-3 ORIGINAL ARTICLE Comparison of Endoscopic and Clinical Characteristics of Patients with Familial and Sporadic Barrett s Esophagus Samuel Ash Benjamin J. Vaccaro Mary Kay Dabney
More informationBarrett esophagus. Bible class Inselspital
Barrett esophagus Bible class Inselspital 2015.08.10 Guidelines Definition? BSG: ACG: Definition? BSG: ACG: What are the arguments for and against IM as prerequisite for the Dg? What are the arguments
More informationBarrett s Oesophagus Information Leaflet THE DIGESTIVE SYSTEM. gutscharity.org.
THE DIGESTIVE SYSTEM http://healthfavo.com/digestive-system-for-kids.html This factsheet is about Barrett s Oesophagus Barrett s Oesophagus is the term used for a pre-cancerous condition where the normal
More informationRisk stratification of Barrett s oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study
Risk stratification of using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study Caryn S Ross-Innes*, Hamza Chettouh*, Achilleas Achilleos*, Nuria Galeano-Dalmau, Irene Debiram-Beecham,
More informationManagement of Barrett s Esophagus. Case Presentation
Management of Barrett s Esophagus Lauren B. Gerson MD, MSc Associate Clinical Professor, UCSF Director of Clinical Research Gastroenterology Fellowship Program California Pacific Medical Center San Francisco,
More informationFaculty Disclosure. Objectives. State of the Art #3: Referrals for Gastroscopy (focus on common esophagus problems) 24/11/2014
State of the Art #3: Referrals for Gastroscopy (focus on common esophagus problems) Dr. Amy Morse November 2014 Faculty: Amy Morse Faculty Disclosure Relationships with commercial interests: Grants/Research
More informationTreating Barrett s oesophagus with photodynamic therapy
Understanding NICE guidance Information for people who use NHS services Treating Barrett s oesophagus with photodynamic therapy NICE interventional procedures guidance advises the NHS on when and how new
More informationChallenges for Colorectal Cancer Screening
Challenges for Colorectal Cancer Screening a Biomarker with No Standards! Prof. Emeritus Stephen P. Halloran University of Surrey W. Europe Top 20 Cancers Men Incidence & Mortality (2012) Women World -
More informationUpper Gastrointestinal Tract. Dr. Pascal Juillerat, M.Sc. epidemiology Gastroenterology, clinic for visceral surgery and medicine Inselspital, Bern
Upper Gastrointestinal Tract Dr. Pascal Juillerat, M.Sc. epidemiology Gastroenterology, clinic for visceral surgery and medicine Inselspital, Bern ? https://live.ueg.eu/week/app/ MONDAY Text GENETICS OR
More informationESOPHAGEAL CANCER. Epidemiology 3/22/2017. Esophageal Carcinoma: subtypes. Esophageal Adenocarcinoma (EAC) Epidemiology.
ESOPHAGEAL CANCER Disclosures Sushil Ahlawat, MD, FACP, FASGE, AGAF Associate Professor of Medicine Director of Endoscopy RUTGERS NJMS Nothing to disclose. Esophageal Carcinoma: subtypes Subtype Squamous
More informationIMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS
IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS Dr Elizabeth Smyth Cambridge University Hospitals NHS Foundation Trust ESMO Gastric Cancer Preceptorship Valencia 2018 DISCLOSURES Honoraria for advisory role
More informationIs Radiofrequency Ablation Effective In Treating Barrett s Esophagus Patients with High-Grade Dysplasia?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 12-2016 Is Radiofrequency Ablation Effective
More informationWhat could a public health strategy for weight loss look like? Paul Aveyard Professor of behavioural medicine
What could a public health strategy for weight loss look like? Paul Aveyard Professor of behavioural medicine Conflicts of interest In this research and in other similar research, commercial weight loss
More informationFellow GU Lecture Series, Prostate Cancer. Asit Paul, MD, PhD 02/20/2018
Fellow GU Lecture Series, 2018 Prostate Cancer Asit Paul, MD, PhD 02/20/2018 Disease Burden Screening Risk assessment Treatment Global Burden of Prostate Cancer Prostate cancer ranked 13 th among cancer
More informationCan erythropoietin treatment during antiviral drug treatment for hepatitis C be cost effective?
Below Are Selected Good Abstracts from Digestive Disease Week 2006 Meeting Published in Gut. 2006 April; 55(Suppl 2): A1 A119. http://www.ncbi.nlm.nih.gov/pmc/articles/pmc1859999/?tool=pmcentrez Can erythropoietin
More informationProstate Cancer Screening Where are we? Prof. Bob Steele Professor of Surgery, University of Dundee Independent Chair, UK NSC
Prostate Cancer Screening Where are we? Prof. Bob Steele Professor of Surgery, University of Dundee Independent Chair, UK NSC 1990 Screening The detection of disease in asymptomatic people in order to
More informationNew Developments in the Endoscopic Diagnosis and Management of Barrett s Esophagus
New Developments in the Endoscopic Diagnosis and Management of Barrett s Esophagus Prateek Sharma, MD Key Clinical Management Points: Endoscopic recognition of a columnar lined distal esophagus is crucial
More informationCurrent Management of Low-Grade Dysplasia in Barrett Esophagus
Current Management of Low-Grade Dysplasia in Barrett Esophagus Gary W. Falk, MD, MS Dr Falk is a professor of medicine in the Division of Gastroenterology at the University of Pennsylvania Perelman School
More informationBarrett s Esophagus: What to Do for No Dysplasia, LGD, and HGD?
Barrett s Esophagus: What to Do for No Dysplasia, LGD, and HGD? Nicholas Shaheen, MD, MPH Center for Esophageal Diseases and Swallowing University of North Carolina 1 Outline What are the risks of progression
More informationMissed Lesions at Endoscopy. Dr Russell Walmsley, MD, FRCP, FRACP Gastroenterologist WDHB Chair Endoscopy Guidance Group for New Zealand
Missed Lesions at Endoscopy Dr Russell Walmsley, MD, FRCP, FRACP Gastroenterologist WDHB Chair Endoscopy Guidance Group for New Zealand Missed Lesions at Endoscopy Is there a problem? With Gastroscopy
More informationPersonalized Aspirin Therapy
Personalized Aspirin Therapy Nadir Arber, MD, MSc, MHA Head - Integrated Cancer Prevention Center Tel Aviv Medical Centre and Tel Aviv University Heidelberg 2014 CRC is Preventable Early detection Chemoprevention
More informationSurgery for Gastric and Oesophageal Cancer
Surgery for Gastric and Oesophageal Cancer Trends in cancer mortality, England and Wales SMR base 1980 Oesophago-Gastric Cancer The National Problem 5 th commonest malignancy 4 th commonest cause of death
More informationEarly Detection of Lung Cancer: Metabolic Biomarkers for High Risk Screening
Early Detection of Lung Cancer: Metabolic Biomarkers for High Risk Screening Dr Paul Lewis Senior Lecturer in Biomedical Informatics PI, Pathology & Toxicology Informatics Group p.d.lewis@swansea.ac.uk
More informationCitation for published version (APA): Phoa, K. Y. N. (2014). Endoscopic management of Barrett s esophagus with dysplasia
UvA-DARE (Digital Academic Repository) Endoscopic management of Barrett s esophagus with dysplasia Phoa, Nadine Link to publication Citation for published version (APA): Phoa, K. Y. N. (2014). Endoscopic
More informationOesophagus and Stomach update dysplasia and early cancer
Oesophagus and Stomach update dysplasia and early cancer Dr Tim Bracey STR teaching 13/4/16 Please check pathkids.com for previous talks One of the biggest units in the country (100 major resections per
More informationEarly detection and treatment for Esophageal Cancer in Africa
Early detection and treatment for Esophageal Cancer in Africa Dr Michael Mwachiro Tenwek Hospital NCI-IARC ESCC Tumor Workshop Where is Tenwek Hospital? Tenwek Nairobi Tenwek Hospital Identification of
More informationRFA and Cyrotherapy for Esophageal Disease
RFA and Cyrotherapy for Esophageal Disease Daniel L. Miller MD Chief, General Thoracic Surgery WellStar Healthcare System/ Mayo Clinic Care Network Clinical Professor of Surgery Medical College of Georgia/
More informationTowards A New Generation of Cancer Models UK Interdisciplinary Breast Cancer Symposium th January Mathew Garnett
Towards A New Generation of Cancer Models UK Interdisciplinary Breast Cancer Symposium 15-16 th January 2017 Mathew Garnett 1 Precision Cancer Medicine molecular biomarker Diagnosis Prognosis Therapy 2
More informationEditorial: Advanced endoscopic therapeutics in Barrett s neoplasia; where are we now and where are we heading?
Editorial: Advanced endoscopic therapeutics in Barrett s neoplasia; where are we now and where are we heading? Dr. Gaius Longcroft-Wheaton MB,BS, MD, MRCP(UK), MRCP(Gastro) Consultant gastroenterologist
More informationWhen to Refer for OGD and the Work Up of Upper GI Malignancies
When to Refer for OGD and the Work Up of Upper GI Malignancies Dr Hong Qiantai Registrar, Department of Surgery GP Forum 27 May 2017 38 year old female, non-smoker, BMI 29 Works as investment banker Presents
More informationPatient information leaflet. Royal Surrey County Hospital. NHS Foundation Trust. Barrett s Oesophagus. Endoscopy Department
Patient information leaflet Royal Surrey County Hospital NHS Foundation Trust Barrett s Oesophagus Endoscopy Department You will only be given this leaflet if you are suspected of having or you have been
More informationPros and cons of liquid biopsy: Ready to replace tissue?
Pros and cons of liquid biopsy: Ready to replace tissue? 2-Day Molecular Biologists Symposium: Liquid biopsies Federico Rojo Enterprise Interest No disclosures. Biological limitations for molecular testing:
More informationThe New Grade A: USPSTF Updated Colorectal Cancer Screening Guidelines, What does it all mean?
The New Grade A: USPSTF Updated Colorectal Cancer Screening Guidelines, What does it all mean? Robert A. Smith, PhD Cancer Control, Department of Prevention and Early Detection American Cancer Society
More informationGERD DIAGNOSIS & TREATMENT DISCLOSURES 4/18/2018
GERD DIAGNOSIS & TREATMENT Subhash Chandra MBBS Assistant Professor CHI Health Clinic Gastroenterology Creighton University, School of Medicine April 28, 2018 DISCLOSURES None 1 OBJECTIVES Review update
More informationGynecologic Cancers are many diseases. Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine. Speaker Disclosure:
Gynecologic Cancer Care in the Age of Precision Medicine Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine Lee-may Chen, MD Department of Obstetrics, Gynecology & Reproductive
More informationAre You Living with Barrett s Esophagus?
Are You Living with Barrett s Esophagus? Wouldn t you rather live without it? If you re living with Barrett s esophagus you are not alone. Barrett s esophagus is caused by the long-term exposure of your
More informationGynecologic Cancers are many diseases. Speaker Disclosure: Gynecologic Cancer Care in the Age of Precision Medicine. Controversies in Women s Health
Gynecologic Cancer Care in the Age of Precision Medicine Gynecologic Cancers in the Age of Precision Medicine Controversies in Women s Health Lee-may Chen, MD Department of Obstetrics, Gynecology & Reproductive
More informationLIST OF ABBREVIATIONS
Gastroenter oenterology 2005 Royal College of Physicians of Edinburgh Screening and surveillance for upper and lower gastrointestinal cancer JN Plevris Consultant Gastroenterologist and Honorary Senior
More informationAnn Intern Med. 2012;156(5):
Lung Cancer Screening Update Doug Arenberg, M.D. University of Michigan Outline Screening; Some simple but necessary truths Do people benefit from screening? What are the harms (and are they outweighed
More informationNational Oesophago-Gastric Cancer Audit New Patient Registration sheet Patients with Oesophageal High Grade Glandular Dysplasia
National Oesophago-Gastric Cancer Audit New Patient Registration sheet Patients with Oesophageal High Grade Glandular Dysplasia Patient Details Surname: NHS number: Forename: Postcode: Sex: Male Female
More informationPattern of esophageal cancer in tertiary care hospital in North India: a clinicopathological study
International Journal of Research in Medical Sciences Gupta V et al. Int J Res Med Sci. 2017 Apr;5(4):1405-1409 www.msjonline.org pissn 2320-6071 eissn 2320-6012 Original Research Article DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20171235
More informationevidence note Radiofrequency ablation for Barrett s oesophagus with highgrade What is an evidence note Key points Literature search Introduction
In response to an enquiry from the National Cancer Waiting Times Delivery Group What is an evidence note Evidence notes are rapid reviews of published secondary clinical and cost-effectiveness evidence
More informationThe Pathologist s Role in the Diagnosis and Management of Neoplasia in Barrett s Oesophagus Cian Muldoon, St. James s Hospital, Dublin
The Pathologist s Role in the Diagnosis and Management of Neoplasia in Barrett s Oesophagus Cian Muldoon, St. James s Hospital, Dublin 24.06.15 Norman Barrett Smiles [A brief digression - Chair becoming
More informationWhat Is Barrett s Esophagus?
What Is Barrett s Esophagus? Having Barrett s esophagus means the cells lining the esophagus (the tube that links the mouth and the stomach) have changed into types of intestinal cells that are not normal
More informationUnravelling the Molecular Taxonomies of Gastroesophageal Cancers
Unravelling the Molecular Taxonomies of Gastroesophageal Cancers Patrick Tan, MD PhD Professor, Duke-NUS Medical School Deputy Executive Director, Biomedical Research Council, Agency for Science, Technology
More informationGI CANCER SCREENING- Is It Worth It? Sylvia M. Oats, MSN, APRN, ANP-BC Susan H. Miedecke, MSN, APRN, FNP-BC Gastroenterology Clinic of Acadiana
GI CANCER SCREENING- Is It Worth It? Sylvia M. Oats, MSN, APRN, ANP-BC Susan H. Miedecke, MSN, APRN, FNP-BC Gastroenterology Clinic of Acadiana Life is a sexually transmitted disease, and the mortality
More informationOesophago gastric cancer the disease and the challenges. Muntzer Mughal
Oesophago gastric cancer the disease and the challenges Muntzer Mughal Oesophago gastric cancer How common is it? What causes it? What are the symptoms? How is it treated? Recent advances in: Detection
More informationDefinition of GERD American College of Gastroenterology
Definition of GERD American College of Gastroenterology GERD is defined as chronic symptoms or mucosal damage produced by the abnormal reflux of gastric contents into the esophagus DeVault et al. Am J
More informationDIAGNOSTICS ASSESSMENT PROGRAMME Diagnostics consultation document
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE DIAGNOSTICS ASSESSMENT PROGRAMME Diagnostics consultation document Molecular testing strategies for Lynch syndrome in The National Institute for Health
More informationCervical Cancer Screening. David Quinlan December 2013
Cervical Cancer Screening David Quinlan December 2013 Cervix Cervical Cancer Screening Modest variation provincially WHO and UK begin at 25 stop at 60 Finland begin at 30 stop at 60 Rationale for
More informationJoel A. Ricci, MD SUNY Downstate Medical Center Department of Surgery
Joel A. Ricci, MD SUNY Downstate Medical Center Department of Surgery Norman Barrett (1950) described the esophagus as: that part of the foregut, distal to the cricopharyngeal sphincter, which is lined
More informationBurning Issues in the Esophagus
Burning Issues in the Esophagus Elizabeth Montgomery, MD Johns Hopkins Medical Institutions Dr. Montgomery reports no relevant financial relationships with commercial interests. Squamous Epithelium Muscularis
More informationMolecular Testing in Lung Cancer
Molecular Testing in Lung Cancer Pimpin Incharoen, M.D. Assistant Professor, Thoracic Pathology Department of Pathology, Ramathibodi Hospital Genetic alterations in lung cancer Source: Khono et al, Trans
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationGUIDANCE ON THE INDICATIONS FOR DIAGNOSTIC UPPER GI ENDOSCOPY, FLEXIBLE SIGMOIDOSCOPY AND COLONOSCOPY
Position Statement produced by BSG, AUGIS and ACPGBI GUIDANCE ON THE INDICATIONS FOR DIAGNOSTIC UPPER GI ENDOSCOPY, FLEXIBLE SIGMOIDOSCOPY AND COLONOSCOPY Introduction In 2011 the Independent Practice
More informationCT PET SCANNING for GIT Malignancies A clinician s perspective
CT PET SCANNING for GIT Malignancies A clinician s perspective Damon Bizos Head, Surgical Gastroenterology Charlotte Maxeke Johannesburg Academic Hospital Case presentation 54 year old with recent onset
More informationEsophageal Cancer: Iran Story
Esophageal Cancer: Iran Story Reza Malekzadeh, MD Digestive Disease Research Institute, Tehran University of Medical Sciences Arash Etemadi, MD PhD National Cancer Institute, NIH, Bethesda, MD Esophageal
More informationJuly 19, Division of Dockets Management Food and Drug Administration 5630 Fishers Lane Room 1061, HFA-305 Rockville, Maryland 20852
July 19, 2017 Division of Dockets Management Food and Drug Administration 5630 Fishers Lane Room 1061, HFA-305 Rockville, Maryland 20852 Re: Comments on Citizen s Petition #FDA-2017-P-2733 Herein, the
More informationPrevention of Bowel Cancer: which patients do I send for colonoscopy?
Prevention of Bowel Cancer: which patients do I send for colonoscopy? Dr Chris Groves Consultant Gastroenterologist and Honorary Senior Lecturer St George s Hospital and Medical School Director, SW London
More informationAn Approach to Pancreatic Cysts. Introduction
An Approach to Pancreatic Cysts Nalini M. Guda, MD Aurora St. Luke s Medical Center, Milwaukee Clinical Adjunct Professor of Medicine, University of Wisconsin School of Medicine and Public Health Introduction
More informationGeisinger Clinic Annual Progress Report: 2011 Nonformula Grant
Geisinger Clinic Annual Progress Report: 2011 Nonformula Grant Reporting Period July 1, 2012 June 30, 2013 Nonformula Grant Overview The Geisinger Clinic received $1,000,000 in nonformula funds for the
More informationBasic Economic Analysis. David Epstein, Centre for Health Economics, York
Basic Economic Analysis David Epstein, Centre for Health Economics, York Contents Introduction Resource use and costs Health Benefits Economic analysis Conclusions Introduction What is economics? Choices
More informationConsensus statement between CM-Path, CRUK and the PHG Foundation following on from the Liquid Biopsy workshop on the 8th March 2018
Consensus statement between CM-Path, CRUK and the PHG Foundation following on from the Liquid Biopsy workshop on the 8th March 2018 Summary: This document follows on from the findings of the CM-Path The
More informationAlberta Colorectal Cancer Screening Program (ACRCSP) Post Polypectomy Surveillance Guidelines
Alberta Colorectal Cancer Screening Program (ACRCSP) Post Polypectomy Surveillance Guidelines June 2013 ACRCSP Post Polypectomy Surveillance Guidelines - 2 TABLE OF CONTENTS Background... 3 Terms, Definitions
More informationMedicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
More informationEsophageal cancer: Biology, natural history, staging and therapeutic options
EGEUS 2nd Meeting Esophageal cancer: Biology, natural history, staging and therapeutic options Michael Bau Mortensen MD, Ph.D. Associate Professor of Surgery Centre for Surgical Ultrasound, Upper GI Section,
More informationAdvances in gastric cancer: How to approach localised disease?
Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation
More informationUK Bowel Cancer screening Dr Voi Shim Wong BsC MD FRCP. Consultant Gastroenterologist Accredited BCSP colonoscopist Whittington + UCL Hospitals
UK Bowel Cancer screening 2017 Dr Voi Shim Wong BsC MD FRCP Consultant Gastroenterologist Accredited BCSP colonoscopist Whittington + UCL Hospitals Bowel Cancer Contents UK Bowel Cancer Screening Programme
More informationInterventions to Improve Follow-up of Positive Results on Fecal Blood Tests
Interventions to Improve Follow-up of Positive Results on Fecal Blood Tests Results of a systematic review, Kaiser experience, and implications for the Canton of Vaud Kevin Selby, M.D. Kevin.Selby@hospvd.ch
More information